ADCT (ADC Therapeutics) LT-Debt-to-Total-Asset : 0.45 (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ADC Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2025 was 0.45.

ADC Therapeutics's long-term debt to total assets ratio increased from Mar. 2024 (0.40) to Mar. 2025 (0.45). It may suggest that ADC Therapeutics is progressively becoming more dependent on debt to grow their business.

ADC Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for ADC Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics LT-Debt-to-Total-Asset Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.22

0.21

0.24

0.35

0.38

ADC Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.40	0.33	0.35	0.38	0.45

ADC Therapeutics LT-Debt-to-Total-Asset Calculation

ADC Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	121.627	/	321.98
	=	0.38

ADC Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (Q: Mar. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )	/	Total Assets (Q: Mar. 2025 )
	=	121.73	/	272.539
	=	0.45

ADC Therapeutics (NYSE:ADCT) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ADC Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).